Real Life Use of Omalizumab in Chronic Urticaria
Launched by UNIVERSITY HOSPITAL, MONTPELLIER · Oct 6, 2020
Trial Information
Current as of June 04, 2025
Unknown status
Keywords
ClinConnect Summary
Chronic urticaria affects up to 1% of the population. Rarely, chronic urticaria may be refractory to updosing four-fold antihistamine drugs and then can be improved with subcutaneous OMALIZUMAB. OMALIZUMAB is available for chronic urticaria since 2015. It is an IgG1 monoclonal antibody targeting IgE and administrated every 4 weeks which represent a cost of nearly 800€/month excluding nurse fees. Efficacy and good tolerance have already been demonstrated in real-life large cohorts of patients. A 6 months treatment duration is proposed before evaluating the efficacy and discontinuating the tr...
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • chronic spontaneous or inducible urticaria
- • treated with omalizumab
- • at least once between January the 1st 2010 and july 2020.
- Exclusion criteria:
- • unknown intiation and discontinuation date of omalizumab
- • omalizumab initiated for asthma
- • other diagnosis (vascularitis, aquagenic pruritus)
About University Hospital, Montpellier
The University Hospital of Montpellier is a leading academic medical institution dedicated to advancing healthcare through innovative research and clinical trials. Renowned for its commitment to patient-centered care, the hospital collaborates with multidisciplinary teams to explore cutting-edge treatments and therapies across various medical fields. By integrating clinical practice with education and research, the University Hospital of Montpellier aims to enhance health outcomes and contribute to the scientific community's understanding of complex medical conditions. Its robust infrastructure and expertise make it a pivotal player in the landscape of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montpellier, , France
Patients applied
Trial Officials
Aurélie Du Thanh, MD, PhD
Principal Investigator
University Hospitals of Montpellier
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials